Therapeutic potential of cannabinoids in glaucoma
T Lindner, D Schmidl, L Peschorn, V Pai… - Pharmaceuticals, 2023 - mdpi.com
Glaucoma is a leading cause of irreversible blindness worldwide. To date, intraocular
pressure (IOP) is the only modifiable risk factor in glaucoma treatment, but even in treated …
pressure (IOP) is the only modifiable risk factor in glaucoma treatment, but even in treated …
[HTML][HTML] Glaucoma: Novel antifibrotic therapeutics for the trabecular meshwork
M Qin, C Yu-Wai-Man - European Journal of Pharmacology, 2023 - Elsevier
Glaucoma is a chronic and progressive neurodegenerative disease characterized by the
loss of retinal ganglion cells and visual field defects, currently affecting around 1% of the …
loss of retinal ganglion cells and visual field defects, currently affecting around 1% of the …
LC-MS/MS quantitation of non-psychotropic cannabinoid cannabidiol in aqueous humor
AS Aebersold, A Kumar, ZH Song - Journal of pharmaceutical and …, 2023 - Elsevier
Cannabidiol (CBD) is the most abundant non-psychotropic phytocannabinoid isolated from
Cannabis sativa. To support preclinical studies of ocular pharmacology of CBD, a …
Cannabis sativa. To support preclinical studies of ocular pharmacology of CBD, a …